This site is intended for health professionals only
Oral rivaroxaban tablets have been recommended by the National
Institute for Health and Clinical Excellence (NICE), the UK drug
recommendation body, as a new treatment option for prevention of
stroke and systemic embolism in patients with non-valvular atrial
fibrillation (AF) with one or more risk factors.
The NICE recommendation gives eligible patients cared for by the
UK health service with non-valvular AF in England and Wales
access to rivaroxaban – the first one tablet per day, oral stroke
prevention medicine since the introduction of warfarin in the 1950s.
NICE estimates that almost half (46%) of AF patients who should be
receiving warfarin are not currently taking it.